



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Intensity Modulated Radiotherapy - IMRT - Central Nervous System Tumors

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Forms](#)

Policy Number: 910

BCBSA Reference Number: 8.01.59

NCD/LCD: N/A

Related Policies

- Clinical Exception and Notification Form for Intensity Modulated Radiation Therapy (IMRT), [#325](#)
- IMRT of the Prostate, [#090](#)
- IMRT of the Breast and Lung, [#163](#)
- IMRT of the Head and Neck or Thyroid, [#164](#)
- IMRT of the Abdomen and Pelvis, [#165](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

IMRT may be **MEDICALLY NECESSARY** for the treatment of tumors of the central nervous system when the tumor is in close proximity to organs at risk and 3-D CRT planning is not able to meet dose volume constraints for normal tissue tolerance as noted in the following tables:

For tumors of the central nervous system:

Tissue	Dose/Volume Threshold
Lenses	3D results in a dose ≥ 7 Gy
Retinae or Globes	3D results in a dose ≥ 45 Gy
Optic nerves/chiasm	3D results in a dose ≥ 54 Gy
Brainstem	3D results in a dose ≥ 54 Gy
Head and Neck IMRT	covered if head and neck structures would receive any radiation via 3D

Please note: [Clinical Exception and Notification form \(#325\)](#) **must** be filled out and submitted prior to all IMRT treatments.

Clinical Exception and Notification Form

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Providers **must** submit a request for an exception for a non-covered indication by completing the clinical exception and notification form. [Click here for the IMRT Policy and Notification exception and notification form \(#325\)](#).

Providers **must** complete the Clinical Exception and Notification Form when requesting coverage:

- For medically necessary indications described in medical policy 910, IMRT - Central Nervous System Tumors.
- For not medically necessary and investigational indications, described in medical policy 910, IMRT - Central Nervous System Tumors.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** if the procedure is performed inpatient.

Outpatient

- For services described in this policy, see below for situations where prior authorization might be required if the procedure is performed outpatient.

	Outpatient
Commercial Managed Care (HMO and POS)	Providers must complete the Clinical Exception and Notification Form prior to service.
Commercial PPO and Indemnity	Providers must complete the Clinical Exception and Notification Form prior to service.
Medicare HMO BlueSM	Prior authorization is not required .
Medicare PPO BlueSM	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple

77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
-------	--

HCPCS Codes

HCPCS codes:	Code Description
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

Description

RADIOTHERAPY AND BRAIN TUMORS

The standard approach to treat brain tumors depends on the type and location of the tumor. For glioblastoma multiforme, a high-grade malignant tumor, treatment is multimodal, with surgical resection followed by adjuvant radiotherapy (RT) and chemotherapy.

For benign and low-grade brain tumors, gross total resection remains the primary goal. However, RT may be used in select cases. Some examples are: when total resection is not possible, when a more conservative surgical approach may be necessary to achieve long-term treatment goals, and when atypical tumors may need RT even after gross total resection to reduce the risk of local recurrence. Therefore, RT, either definitive or in the postoperative adjuvant setting, remains an integral component in the management of residual, recurrent, and/or progressive benign and low-grade brain tumors for maximizing local control.

Brain metastases occur in up to 40% of adults with cancer and can shorten survival and detract from the quality of life. Many patients who develop brain metastases will die of progressive intracranial disease. Among patients with good performance status, controlled extracranial disease, favorable prognostic features, and a solitary brain metastasis, randomized studies have shown that surgical excision followed by whole-brain radiotherapy (WBRT) prolongs survival. Stereotactic radiosurgery can replace surgery in certain circumstances, delivering obliterated high single doses to discrete metastases. For bulky cerebral metastases, level 1 evidence has also shown that delivering a higher radiation dose with an SRS boost is beneficial in addition to standard WBRT. The use of a concomitant boost with intensity-modulated radiotherapy (IMRT) during WBRT has been attempted to improve overall local tumor control without the use of stereotactic radiosurgery to avoid additional planned radiation after WBRT (“phase 2” or SRS) and its additional labor and expense. Another indication for the use of IMRT in WBRT is to avoid radiation exposure to the hippocampus. It is thought that avoiding the hippocampus may minimize cognitive decline associated with WBRT.

RADIOTHERAPY TECHNIQUES

Conventional External-Beam Radiotherapy

Methods to plan and deliver RT have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed *conventional external-beam radiotherapy*.

Three-Dimensional Conformal Radiotherapy

Treatment planning evolved by using 3-dimensional images, typically from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each

shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed *3-dimensional conformal radiotherapy (3D-CRT)*.

Intensity-Modulated Radiotherapy

IMRT, which uses computer software and CT and magnetic resonance images, offers better conformality than 3D-CRT because it modulates the intensity of the overlapping radiation beams projected on the target and uses multiple shaped treatment fields. Treatment planning and delivery are more complex, time-consuming, and labor-intensive for IMRT than for 3D-CRT. The technique uses a multileaf collimator (MLC), which, when coupled with a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at risk, computer software optimizes the location, shape, and intensities of the beam ports to achieve the treatment plan’s goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding, normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.

Technologic developments have produced advanced techniques that may further improve RT treatment by improving dose distribution. These techniques are considered variations of IMRT. Volumetric modulated arc therapy delivers radiation from a continuous rotation of the radiation source. The principal advantage of volumetric modulated arc therapy is greater efficiency in treatment delivery time, reducing radiation exposure and improving target radiation delivery due to less patient motion. Image-guided RT involves the incorporation of imaging before and/or during treatment to deliver RT to the target volume more precisely.

IMRT methods to plan and deliver RT are not uniform. IMRT may use beams that remain on as MLCs move around the patient (dynamic MLC) or that are off during movement and turn on once the MLC reaches prespecified positions (“step and shoot” technique). A third alternative uses a very narrow single beam that moves spirally around the patient (tomotherapy). Each method uses different computer algorithms to plan treatment and yields somewhat different dose distributions in and outside the target. Patient position can alter target shape and thus affect treatment plans. Treatment plans are usually based on 1 imaging scan, a static 3D-CT image. Current methods seek to reduce positional uncertainty for tumors and adjacent normal tissues by various techniques. Patient immobilization cradles and skin or bony markers are used to minimize day-to-day variability in patient positioning. In addition, many tumors have irregular edges that preclude drawing tight margins on CT scan slices when radiation oncologists contour the tumor volume. It is unknown whether omitting some tumor cells or including some normal cells in the resulting target affects outcomes of IMRT.

Summary

For individuals who have malignant brain tumors who receive IMRT, the evidence includes dose-planning studies, nonrandomized comparison studies, and case series. Relevant outcomes are overall survival, disease-specific survival, morbid events, functional outcomes, and treatment-related morbidity. Case series results have consistently shown with low radiation toxicity but have not demonstrated better tumor control or improved survival with IMRT. Dose-planning studies have shown that IMRT delivers adequate radiation doses to tumors while simultaneously reducing radiation exposure to sensitive brain areas. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have benign brain tumors who receive IMRT, the evidence includes case series. Relevant outcomes are overall survival, disease-specific survival, functional outcomes, and treatment-

related morbidity. Case series results have consistently shown low radiation toxicity but have not demonstrated better tumor control or improved survival with IMRT vs other radiotherapy techniques. It is expected that the dose-planning studies evaluating IMRT in patients with malignant tumors should generalize to patients with benign brain tumors because the benefit of minimizing radiation toxicity to sensitive brain areas is identical. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have brain tumor metastases who receive IMRT to avoid hippocampal exposure, the evidence includes nonrandomized comparison studies and case series. Relevant outcomes are overall survival, disease-specific survival, functional outcomes, and treatment-related morbidity. One prospective nonrandomized comparison study using IMRT to avoid hippocampal exposure showed a less cognitive decline with IMRT than with a prespecified historical control. Limitations of the historical control design and other aspects of the study make conclusions uncertain. The role of hippocampal radiation exposure as a cause of cognitive decline is less certain; thus, more definitive studies are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
9/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
9/2016	Clarified coding information.
2/2016	Local Coverage Determination (LCD) for Intensity Modulated Radiation Therapy (IMRT) (L3244) removed. 2/1/2016
6/2015	BCBSA National medical policy review. Title changed from "radiation therapy" to "radiotherapy." Effective 6/1/2015.
1/2015	Clarified coding information.
8/2014	Clinical exception and notification clarified. Medicare LCD added.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
6/2013	New references from BCBSA National medical policy.
2/04/2013	New policy describing coverage indications.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Amelio D, Lorentini S, Schwarz M, et al. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. *Radiother Oncol*. Dec 2010;97(3):361-369. PMID 20926149
2. Gupta T, Wadasadawala T, Master Z, et al. Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation. *Int J Radiat Oncol Biol Phys*. Feb 1 2012;82(2):756-764. PMID 21345610
3. Edwards AA, Keggin E, Plowman PN. The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastases. *Br J Radiol*. Feb 2010;83(986):133-136. PMID 20019176
4. Fuller CD, Choi M, Forthuber B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. *Radiat Oncol*. Jul 14 2007;2:26. PMID 17629934

5. MacDonald SM, Ahmad S, Kachris S, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. *J Appl Clin Med Phys*. Apr 19 2007;8(2):47-60. PMID 17592465
6. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. *Int J Radiat Oncol Biol Phys*. Mar 1 2006;64(3):892-897. PMID 16458777
7. Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. *Am J Clin Oncol*. Apr 2014;37(2):177-181. PMID 23211224
8. Milker-Zabel S, Zabel-du Bois A, Huber P, et al. Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. *Int J Radiat Oncol Biol Phys*. Jul 1 2007;68(3):858-863. PMID 17379447
9. Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. *Int J Radiat Oncol Biol Phys*. Jan 01 2007;67(1):232-239. PMID 17084541
10. Sajja R, Barnett GH, Lee SY, et al. Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. *Technol Cancer Res Treat*. Dec 2005;4(6):675-682. PMID 16292888
11. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. *J Clin Oncol*. Dec 1 2014;32(34):3810-3816. PMID 25349290
12. Zhou L, Liu J, Xue J, et al. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. *Radiat Oncol*. May 21 2014;9:117. PMID 24884773
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2018. https://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed June 13 2018.